TMEM97 and ovarian cancer: In an attempt to further improve the therapeutic index of cancer drugs and to minimize off-site toxicities, our laboratory has developed a drug delivery concept that is based on the chemical conjugation of small molecule compounds, such as the SMAC mimetic SW IV-52, to ligands, e.g. SW43 to the sigma-2 receptor - highly upregulated in a number of solid tumors, including ovarian cancer [30].